Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells

Despite the benefits of imatinib for treating gastrointestinal stromal tumors (GIST), the prognosis for high risk GIST and imatinib-resistant (IR) GIST remains poor. The mechanisms of imatinib resistance have not yet been fully clarified. The aim of the study was to establish imatinib-resistant cell...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sako, Hiroyuki, Fukuda, Kazumasa, Saikawa, Yoshiro, Nakamura, Rieko, Takahashi, Tsunehiro, Wada, Norihito, Kawakubo, Hirohumi, Takeuchi, Hiroya, Ohmori, Tai, Kitagawa, Yuko
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2014
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4164645/
https://ncbi.nlm.nih.gov/pubmed/25221952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0107613
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items